NON-ALCOHOLIC FATTY LIVER DISEASES AS A LEADING CAUSE TO LIVER CIRRHOSIS
DOI:
https://doi.org/10.37547/Keywords:
Non-alcoholic fatty liver disease, NAFLD, NASH, liver cirrhosis, metabolic syndrome, epidemiology, pathogenesisAbstract
Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent chronic liver disorder globally, closely associated with obesity, insulin resistance, and metabolic syndrome. This review aims to analyze NAFLD as a leading cause of liver cirrhosis by summarizing current evidence on its epidemiology, risk factors, pathogenesis, and clinical significance. Epidemiological studies indicate that approximately 24–30% of adults worldwide are affected by NAFLD, with prevalence rising even among adolescents and young adults. Key mechanisms driving disease progression include hepatic fat accumulation, insulin resistance, oxidative stress, and chronic inflammation. NAFLD can progress from simple steatosis to non-alcoholic steatohepatitis (NASH), advanced fibrosis, and ultimately cirrhosis, leading to significant morbidity and mortality. Early recognition, lifestyle modification, and targeted interventions are essential to reduce the clinical burden and prevent long-term hepatic complications.
Downloads
References
1. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease — Meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
2. Estes C., Anstee Q.M., Arias-Loste M.T., Bantel H., Bellentani S., Caballeria J., et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, UK, and USA. J Hepatol. 2018;69(4):896–904. doi:10.1016/j.jhep.2018.05.036
3. Powell E.E., Wong V.W.S., Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–2224. doi:10.1016/S0140-6736(20)32511-3
4. Friedman S.L., Neuschwander-Tetri B.A., Rinella M., Sanyal A.J. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–922. doi:10.1038/s41591-018-0104-9
5. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–1465. doi:10.1038/ng.257
6. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2020;17(11):645–659. doi:10.1038/s41575-020-00351-6
7. Younossi Z.M., Stepanova M., Ong J., Trimble G., AlQahtani S., Younossi I., et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–755.e3. doi:10.1016/j.cgh.2018.05.057
8. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., et al. A multi-society Delphi consensus statement on new nomenclature for steatotic liver disease. Hepatology. 2023;78(6):1966-1980. doi:10.1097/HEP.0000000000000520
9. Cusi K., Isaacs S., Barb D., Basu R., Caprio S., Garvey W.T., et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. Endocr Pract. 2022;28(5):528-562. doi:10.1016/j.eprac.2022.03.010
10. World Health Organization. Global report on metabolic risk factors and non-communicable diseases: current trends and health priorities. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO.
11.Loomba R., Friedman S.L., Shulman G.I. Mechanisms and disease progression in nonalcoholic steatohepatitis: New insights into therapeutic targets. Nature Reviews Disease Primers. 2021;7(1):1-24. doi:10.1038/s41572-020-00243-x
12. Eslam M., Newsome P.N., Sarin S.K., Anstee Q.M., Targher G., Romero-Gomez M., et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209. doi:10.1016/j.jhep.2020.03.039
13. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L., et al. Weight Loss Through Lifestyle Modification Significantly Improves Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2023;164(2):300-315. doi:10.1053/j.gastro.2022.10.035
14. Newsome P.N., Sasso M., Deeks J.J., Paredes A., Boursier J., Chan W.K., et al. Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). British Society of Gastroenterology. 2024;73(8):1420-1435. doi:10.1136/gutjnl-2023-331520
15. Dufour J.F., Scherer R., Beuers U., Bugianesi E., Carrat F., Carbone M., et al. The liver in systemic diseases: state of the art and future perspectives. JHEP Reports. 2022;4(3):100424. doi:10.1016/j.jhepr.2021.100424
